I'm LongbridgeAI, I can summarize articles.FDA accepted the BLA resubmission for RP1 in advanced melanoma, with a decision expected by August 2026. Cash reserves declined to $268.9 million, funding operations into early 2027. RP1 and RP2 clinical programs showed strong survival and response rates in recent trials.Original document: Replimune Group, Inc. [REPL] SEC 8-K Current Report — Jul. 9 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
FDA accepted the BLA resubmission for RP1 in advanced melanoma, with a decision expected by August 2026. Cash reserves declined to $268.9 million, funding operations into early 2027. RP1 and RP2 clinical programs showed strong survival and response rates in recent trials.
Original document: Replimune Group, Inc. [REPL] SEC 8-K Current Report — Jul. 9 2026